Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase I/II Clinical Trial of PT-112 Combine With Gemcitabine Injection for Advanced Solid Tumors

NCT05357196 is registered in ClinicalTrials.gov with SciClone Pharmaceuticals as lead sponsor.

NCT NCT05357196
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05357196 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase I/II Clinical Trial of PT-112 Combine With Gemcitabine Injection for Advanced Solid Tumors
Lead sponsor
SciClone Pharmaceuticals
Phase
Phase 1/2
Overall status
Unknown status
Start date
April 13, 2020
Completion date
April 28, 2023
Enrollment
68 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer